Old drug, new target: can a vitamin a derivative boost pancreatic cancer treatment?
NCT ID NCT04241276
Summary
This trial is testing if adding a repurposed drug called ATRA to standard chemotherapy (gemcitabine and nab-paclitaxel) is more effective for controlling locally advanced pancreatic cancer. About 170 patients will be randomly assigned to receive either the standard two-drug combo or the new three-drug combo. The main goal is to see if the three-drug combination helps keep the cancer from growing for a longer period of time (progression-free survival) compared to standard treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Barts NHS Trust
London, United Kingdom
Conditions
Explore the condition pages connected to this study.